Skip to main content
SpringerLink
Log in

Does the presence of heparin and dexamethasone in the vitrectomy infusate reduce reproliferation in proliferative vitreoretinopathy?

  • Clinical Investigation
  • Published:
Graefe's Archive for Clinical and Experimental Ophthalmology Aims and scope Submit manuscript

Abstract

• Background: Reproliferation following vitrectomy for proliferative vitreoretinopathy (PVR) causes redetachment in up to 55% of cases. Heparin and corticosteroids have each been shown to inhibit the development of proliferative vitreoretinopathy (PVR) in experimental models. However, little information is available on the use of these agents in humans. • Methods: In this pilot study, 62 eyes of 62 patients with severe PVR requiring vitrectomy were prospectively randomized to receive either BSS Plus (control) or BSS Plus with heparin and dexamethasone (HD) in the infusate. • Results: After one operation, the retina was reattached in 42 (71%) of 59 eyes: 22 (65%) of 34 eyes in the control group and 20 (80%) of 25 eyes in the HD group (P = 0.16). Reproliferation developed in 26.5% of the control group (9 of 34 eyes) and 16% of the HD group (4 of 25 eyes; P = 0.26). Postoperative hemorrhage was significantly more frequent in the HD group (P = 0.02) but did not influence final visual or anatomic outcome. Hypotony was less frequent in the HD group but the difference was not significant (P = 0.063). • Conclusion: The trend from this randomized pilot study suggests that HD supplementation of the vitrectomy infusate may reduce the reproliferation rate in PVR and possibly reduce the rate of hypotony. Postoperative hemorrhage was more frequent with HD but did not cause redetachment or alter visual outcome. A multicenter trial involving more patients would be required to better evaluate the efficacy of HD as a pharmacologic adjunct to PVR surgery.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Berman DH, Gombos GM (1989) Proliferative vitreoretinopathy: does low-dose colchicine have an inhibitory effect? A controlled study in humans. Ophthalmic Surg 20: 268–272

    Google Scholar 

  2. Blankenship GW (1991) Evaluation of a single intravitreal injection of dexamethasone phosphate in vitrectomy surgery for diabetic retinopathy complications. Graefe's Arch Clin Exp Ophthalmol 229: 62–65

    Google Scholar 

  3. Blumenkranz MS, Claflin A, Hajek AS (1984) Selection of therapeutic agents for intraocular proliferative disease: cell culture evaluation. Arch Ophthalmol 102: 598–604

    Google Scholar 

  4. Blumenkranz M, Hernandez E, Ophir A, Norton EW (1984) 5-Fluorouracil: new applications in complicated retinal detachment for an established antimetabolite. Ophthalmology 91: 122–129

    Google Scholar 

  5. Blumenkranz MS, Hartzer MK (1989) The mechanism of action of drugs for the treatment of vitreoretinal scarring. In: Ryan SJ (ed) Retina, vol 3. Mosby, St. Louis, pp 401–411

    Google Scholar 

  6. Blumenkranz MS, Hartzer MK, Iverson D (1992) An overview of potential applications of heparin in vitreoretinal surgery. Retina 12: S71-S74

    Google Scholar 

  7. Campochiaro PA, Glaser BM (1984) Platelet derived growth factor is chemotactic for human retinal pigment epithelial cells. Arch Ophthalmol 102: 1830–1833

    Google Scholar 

  8. Chang S, Ozmert E, Zimmerman NJ (1988) Intraoperative perfluorocarbon liquids in the management of proliferative vitreoretinopathy. Am J Ophthalmol 106: 668–674

    Google Scholar 

  9. Gospodarowicz D, Cheng J (1986) Heparin protects basic and acidic FGF from inactivation. J Cell Physiol 128: 475–484

    Google Scholar 

  10. Hirsch J, Ofosu F, Levine M (1987) The development of low molecular heparins for clinical use. In: Verstraete M, Vermylen J, Lijnen H, Arnout J (eds) Thrombosis and haemostasis. Leuven University Press, Leuven, Belgium, pp 325–348

    Google Scholar 

  11. Ishai-Mitchaeli R, Svahn CM, Weber M, et al (1992) Importance of size and sulfation of heparin in release of basic fibroblast growth factor from the vascular endothelium and extracellular matrix. Biochemistry 31: 2080–2088

    Google Scholar 

  12. Johnson R, Balyeat E, Stern WH (1987) Heparin therapy for the prevention of intraocular fibrin membranes. Ophthalmology 94: 597–601

    Google Scholar 

  13. Kwak HW, D'Amico DJ (1992) Evaluation of the retinal toxicity and pharmacokinetics of dexamethasone after intravitreal injection. Arch Ophthalmol 110: 259–266

    Google Scholar 

  14. Lewis H, Aaberg TM (1991) Causes of failure after repeat vitreoretinal surgery for recurrent proliferative vitreoretinopathy. Am J Ophthalmol 111: 15–19

    Google Scholar 

  15. Lewis H, Aaberg TM, Abrams GW (1991) Causes of failure after initial vitreoretinal surgery for severe proliferative vitreoretinopathy. Am J Ophthalmol 111: 8–14

    Google Scholar 

  16. Limb GA, Little BC, Meager A, et al (1991) Cytokines in proliferative vitreoretinopathy. Eye 5: 686–693

    Google Scholar 

  17. Machemer R, Aaberg TM, Freeman HM, et al (1991) An updated classification of retinal detachment with proliferative vitreoretinopathy. Am J Ophthalmol 112: 159–165

    Google Scholar 

  18. Ornitz DM, Yayon A, Flanagan JG, et al (1992) Heparin is required for cell-free binding of basic fibroblast growth factor to a soluble receptor and for mitogenesis in whole cells. Mol Cell Biol 12: 240–247

    Google Scholar 

  19. Raichand M, Peyman GA, Schwartz HR, Chester (1982) Anti-inflammatory action of dexamethasone in vitrectomy infusion fluid. Ophthalmic Surg 13: 493–498

    Google Scholar 

  20. Ruoslahti E, Yamaguchi Y (1991) Proteoglycans as modulators of growth factor activities. Cell 64: 867–869

    Google Scholar 

  21. Tano Y, Sugita G, Abrams G, Machemer R (1980) Inhibition of intraocular proliferations with intravitreal corticosteroids. Am J Ophthalmol 89: 131–136

    Google Scholar 

  22. The Retina Society Terminology Committee (1983) The classification of retinal detachment with proliferative vitreoretinopathy. Ophthalmology 90: 121–125

    Google Scholar 

  23. The Silicone Study Group (1992) Vitrectomy with silicone oil or perfluoropropane gas in eyes with severe proliferative vitreoretinopathy: results of a randomized clinical trial. Silicone Study report 2. Arch Ophthalmol 110: 780–792

    Google Scholar 

  24. Vidaurri-Zeal JS, Glaser BM (1984) Effect of fibrin on morphologic characteristics of retinal pigment epithelial cells. Arch Ophthalmol 102: 1376–1379

    Google Scholar 

  25. Wiedemann P (1992) Growth factors in retinal diseases: proliferative vitreoretinopathy, proliferative diabetic retinopathy, and retinal degeneration. Surv Ophthalmol 36: 373–384

    Google Scholar 

  26. Wiedemann P, Lemmen K, Schmiedl R, Heimann K (1987) Intraocular daunomycin for the treatment and prophylaxis of traumatic proliferative vitreoretinopathy. Am J Ophthalmol 104:10–14

    Google Scholar 

  27. Yayon A, Klagsbrun M, Esko JD, et al (1991) Cell surface, heparin- like molecules are required for binding of basic fibroblast growth factor to its high affinity receptor. Cell 64: 841–848

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. New York Hospital-Cornell University Medical Center, New York, New York, USA

    R. Geoff Williams, Stanley Chang, Mark R. Comaratta & George Simoni

Authors
  1. R. Geoff Williams
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Stanley Chang
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Mark R. Comaratta
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. George Simoni
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Williams, R.G., Chang, S., Comaratta, M.R. et al. Does the presence of heparin and dexamethasone in the vitrectomy infusate reduce reproliferation in proliferative vitreoretinopathy?. Graefe's Arch Clin Exp Ophthalmol 234, 496–503 (1996). https://doi.org/10.1007/BF00184858

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00184858

Keywords

Search

Navigation